Related Experiment Videos

COX-2 and prostanoid receptors: good targets for chemoprevention

Toshihiko Kawamori1, Keiji Wakabayashi

  • 1Cancer Prevention Division, National Cancer Center Research Institute, Tokyo, Japan. tkawamor@gan2.ncc.go.jp

Insights

Selective COX-2 inhibitors show promise in preventing colon and breast cancer. Research indicates the EP1 receptor plays a key role in colon cancer development, suggesting EP1 antagonists as potential chemopreventive agents.

Area of Science:

  • Oncology
  • Pharmacology
  • Gastroenterology

Background:

  • Cyclooxygenase-2 (COX-2) inhibitors have been implicated in colon and breast cancer development.
  • Previous studies demonstrated the inhibitory effects of selective COX-2 inhibitors (nimesulide, celecoxib) on intestinal carcinogenesis.
  • Nimesulide was found to suppress PhIP-induced breast cancer in rats with overexpressed COX-2.

Purpose of the Study:

  • To investigate the role of prostaglandin E2 (PGE2) and its receptors (EP1-4) in colon carcinogenesis.
  • To evaluate the potential of EP1 receptor antagonists as chemopreventive agents for colon cancer.

Main Methods:

  • Utilized receptor knockout mice models.
  • Administered selective EP receptor antagonists.
  • Examined the effects of EP receptors on colon carcinogenesis.

Main Results:

  • The EP1 receptor was identified as playing a pivotal role in colon carcinogenesis.
  • Selective EP1 receptor antagonists demonstrated potential in preventing colon cancer development.

Conclusions:

  • The EP1 receptor is a critical factor in the development of colon cancer.
  • Selective EP1 receptor antagonists represent a promising new class of chemopreventive agents for colon cancer.

Related Concept Videos